Octant Bio

Octant is a small molecule therapeutics company focused on modulating the function of complex cellular mechanisms that drive disease, rather than on binding molecules to purified isolated target proteins. The company engineers biology and chemistry at large scale to alter cellular function directly, and has concentrated its internal pipeline on correcting diseases of protein misfolding and mistrafficking.

The company's disclosed lead program is OCT-980, an oral small molecule designed to correct protein misfolding caused by rhodopsin gene mutations, the underlying cause of rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP). RHO-adRP is described as among the most severe and prevalent forms of inherited retinal disorder in the retinitis pigmentosa group, which causes progressive vision loss and can lead to blindness, and for which no treatment options currently exist. Octant reports preclinical studies showing efficacy, including restoration of retinal structure in animal models, and a favorable safety profile. An integrated Phase 1/2 clinical study is planned; the Phase 1a healthy-volunteer stage was initiated as of the first quarter of 2026 and is registered on ClinicalTrials.gov under identifier NCT07408232.

Business model

The company develops its own internal therapeutic programs, advancing small molecule candidates from discovery into clinical development.

Traction

OCT-980 has completed preclinical studies reported to show efficacy, including restored retinal structure in animal models, and a favorable safety profile; its Phase 1a healthy-volunteer study was initiated as of Q1 2026.

Latest developments

The Phase 1a healthy-volunteer portion of the integrated Phase 1/2 study of OCT-980 was initiated as of Q1 2026 (ClinicalTrials.gov NCT07408232).